Compounds and methods for inhibiting mitotic progression
US-2016185782-A1 · Jun 30, 2016 · US
Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
US9724354B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9724354-B2 |
| Application number | US-201414777888-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 21, 2014 |
| Priority date | Mar 22, 2013 |
| Publication date | Aug 8, 2017 |
| Grant date | Aug 8, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are methods for the treatment of proliferative disorders. Disclosed in particular, are methods for treatment of proliferative disorders such as cancer, by administering an mTORC1/2 inhibitor in combination with a selective inhibitor of Aurora A kinase. Preferred MTORC1/2 inhibitors include MLN0128 and the preferred Aurora A kinase inhibitor of the combination is MLN8237.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a patient suffering from breast cancer, comprising administering to the patient an mTORC1/2 inhibitor in combination with a selective inhibitor of Aurora A kinase, wherein the mTORC1/2 inhibitor is 3-(2-amino-1,3-benzoxazol-5-yl)-1-(propan-2-yl)-1H-pyrazolo [3, 4-d] pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof, and the selective inhibitor of Aurora A kinase is 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid, or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the pharmaceutically acceptable salt is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl] amino}-2-methoxybenzoate.
Assignees
Inventors
Classifications
- A61K31/55Primary
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9724354B2 cover?
- Disclosed are methods for the treatment of proliferative disorders. Disclosed in particular, are methods for treatment of proliferative disorders such as cancer, by administering an mTORC1/2 inhibitor in combination with a selective inhibitor of Aurora A kinase. Preferred MTORC1/2 inhibitors include MLN0128 and the preferred Aurora A kinase inhibitor of the combination is MLN8237.
- Who is the assignee on this patent?
- Millennium Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/55. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).